Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II GCD ± rituximab in relapsed or refractory non-Hodgkin lymphoma
jRCT1041230085Phase 2Active, not recruiting
- Start
- Jan 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, carboplatin, dexamethasone and rituximab in non-Hodgkin lymphoma (NHL). Primary endpoint: complete response rate. Started Jan 2015; status: active, not recruiting.
02
Drugs
gemcitabinecarboplatindexamethasonerituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on jRCT1041230085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041230085.